title: Contemporary management of uterine fibroids: focus on emerging medical treatments.
abstract: OBJECTIVE
  This review provides an overview of therapeutic options, with a specific focus on the emerging role of medical options for UF management.
  
  
  METHODS
  PubMed, Google Scholar, and Cochrane Systematic Reviews were searched for articles published between 1980 and 2013. Relevant articles were identified using the following terms: 'uterine fibroids', 'leiomyoma', 'heavy menstrual bleeding', and 'menorrhagia'. The reference lists of articles identified were also searched for other relevant publications.
  
  
  RESULTS
  Because of the largely benign nature of UFs, the most conservative options that minimize morbidity/risk and optimize outcomes should be considered. Watchful waiting, or no immediate intervention combined with regular follow-up, is an appropriate option for the majority of UF patients who experience no symptoms. For women with symptomatic UFs, the optimal treatment should restore quality of life through rapid relief of UF signs and symptoms, reduce tumor size for a sustained period, and maintain or improve fertility. Invasive surgical treatments, such as hysterectomy, have historically been the mainstay of UF treatment. Less invasive surgical and interventional techniques, such as myomectomy, uterine artery embolization, endometrial ablation, and myolysis provide alternatives to hysterectomy. Until recently, medical management of UFs was characterized by short-term treatments and therapies that provided symptomatic control. In addition to controlling abnormal uterine bleeding, newer medical therapies, including the recently Health-Canada-approved ulipristal acetate, act directly to shrink the tumor. Although no agent is currently approved for such use, emerging evidence suggests the potential for long-term medical management of UFs.
  
  
  CONCLUSIONS
  The advent of novel medical therapies may diminish the long-held reliance on more invasive surgical UF treatment options.
authors.affiliation: Department of Obstetrics & Gynecology, The Ottawa Hospital/University of Ottawa , Canada.
authors.forename: Sukhbir Sony
authors.initials: SS
authors.lastname: Singh
authors.forename: Liane
authors.initials: L
authors.lastname: Belland
mesh_terms: D000328:Adult; D002170:Canada; D005260:Female; D013509:Gynecologic Surgical Procedures; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007889:Leiomyoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008595:Menorrhagia / Q000209:etiology / Q000473:pathology / Q000628:therapy; D009649:Norpregnadienes / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D057832:Watchful Waiting
chemical_list: D006727:Hormone Antagonists; D009649:Norpregnadienes; C555622:ulipristal acetate
keywords: Heavy menstrual bleeding; Medical management; Ulipristal acetate; Uterine fibroids